Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 16Glioma 6Brain Neoplasms 6Medulloblastoma 5Neoplasms 3Recurrence 2Oligodendroglioma 2Central Nervous System Neoplasms 2Sarcoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 15Radiotherapy 10Radiation 8Magnetic Resonance Spectroscopy 7pembrolizumab 5Specimen Handling 5Ipilimumab 3atezolizumab 2Photons 2Nivolumab 2Biopsy 2veliparib 1selinexor 1sargramostim 1plerixafor 1peposertib 1pazopanib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1montanide ISA 51 1liposomal doxorubicin 1gosha-jinki-gan 1fluorodopa F 18 1ferric pyrophosphate 1efineptakin alfa 1cemiplimab 1cabozantinib 1balstilimab 1abexinostat 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Lomustine × 1 year × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡